We serve Chemical Name:3-METHYLBENZOTHIAZOLIUM IODIDE CAS:2786-31-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-METHYLBENZOTHIAZOLIUM IODIDE
CAS.NO:2786-31-4
Synonyms:MFCD00050297;Methylbenzothiazolium iodide;3-Methyl-benzothiazolium-iodid;1-methylbenzothiazolium iodide;Benzothiazole methiodide;EINECS 220-505-1;N-methylbenzothiazolium iodide;3-MethylbenzothiazoliuM Iodide;3-Methyl-benzothiazolium,Jodid
Molecular Formula:C8H8INS
Molecular Weight:277.12500
HS Code:2934999090
Physical and Chemical Properties:
Melting point:204ºC
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:32.12000
Exact Mass:276.94200
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD00050297 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Methyl-benzothiazolium,Jodid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00050297 Use and application,3-Methyl-benzothiazolium-iodid technical grade,usp/ep/jp grade.
Related News: This is of vital important and underlies one of the most solid principles and regulations of modern pharmacy. 3-METHYLBENZOTHIAZOLIUM IODIDE manufacturer In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum. 3-METHYLBENZOTHIAZOLIUM IODIDE supplier You will find the name and amount of the active ingredient contained in the medicine on the package of OTC (over-the-counter) drugs. 3-METHYLBENZOTHIAZOLIUM IODIDE vendor Like Altasciences, Alira has also placed an emphasis on the preclinical setting in recent months with its March hire of Nikole Siegmund as vice president of preclinical development. 3-METHYLBENZOTHIAZOLIUM IODIDE factory Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.
